

**Adult CIRB - Late Phase Emphasis Meeting Agenda**

**May 16, 2024**

---

**I Amendment**

**A031702**, A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) (Version Date 04/10/24)

---

**II Memos**

**S1803**, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC STUDY) (Version Date 05/18/23)

---

**III Continuing Review**

**A092001**, Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy with or Without Immunotherapy for Peritoneal Mesothelioma (Version Date 10/18/23)

---

**IV Continuing Review**

**EAA181**, Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase III Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation (Version Date 10/24/23)

---

**V Continuing Review**

**E2905**, Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and in Combination with Epoetin Alfa (Procrit®) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia (Version Date 08/12/22)